DRUG DISCOVERY FEATURED ARTICLES & APPLICATIONS
-
How To Prepare A Facility For The Biopharmaceutical RevolutionDrug discovery is an inherently inefficient process. It takes thousands of failed compounds before one can get approved as safe and efficacious, and this effort does not come at a low cost. Because of this, the industry is constantly looking for ways to bring safe, compliant, and profitable drugs to market faster and cheaper. Patheon facility in Brisbane, Australia, exemplifies the facility needed to survive the future of pharma. But how did they do it?
-
Pharmaceutical Customers In An Outsourcing Provider Merger -- Part 3 Of Interview With CEO of Newly Formed DPx Holdings B.V.
This final article in our series featuring Jim Mullen, CEO of newly formed DPx Holdings B. V., discusses how to keep the focus on customers during M&A activity, and the broader transformation of sponsor–provider relationships in the pharmaceutical outsourcing industry.
Earlier articles from our interview with Mullen dealt with how an acquisition comes together, and the importance of understanding the relationship between quality, capacity and job security for the early success of any M&A deal. In some ways, we’ve left the most important subject – customers – for last.
-
Quality, Capacity And Job Security In A CMO Industry Merger -- Part 2 Of Our Interview With CEO Of Newly Formed DPx Holdings B.V.
This spring Jim Mullen became CEO of DPx Holdings B.V., formed in a $2.65 billion transaction combining JLL Partners’ assets Patheon and Banner Life Sciences, with Royal DSM’s Pharmaceuticals business. In an interview with Outsourced Pharma, Mullen discusses three key components in a merger: quality, capacity and job security.
With a merger nearing completion and the integration plans underway, Mullen says you have to start with the fundamental ABCs of business. “There are three fundamental questions to get to day one: Do you have the right financial controls? Can you reliably continue to pay your suppliers? Can you receive cash and can you make payroll?
-
Results of First Ever REMOTE Clinical Trial
In the clinical research industry, we’re always evaluating things. We evaluate drugs and biologics. We evaluate medical devices. We also evaluate research techniques. Yes, we try trials. We study studies. That’s what Pfizer was doing when it launched its REMOTE pilot trial in early 2011 – evaluating the effectiveness of a study in which patients participated remotely, without ever having to visit a study site. How would the results of the REMOTE study compare with those of a similar, completed, conventional study? Would this innovative research approach be validated? By Laurie Meehan, Polaris Compliance Consultants, Inc.
-
IMP Shipments: Too Big, Too Costly, Too Bad
A client in the UK was initiating a new clinical trial, and shipping forty-two pallets of the IMP to Marken’s pharmaceutical service depot in the testing region created several challenges.
LATEST NEWS
-
Vertex Submits Supplemental New Drug Application (sNDA) To U.S. Food And Drug Administration For Use Of KALYDECO (ivacaftor) In People 18 And Older With Cystic Fibrosis Who Have The R117H Mutation
Vertex Pharmaceuticals Incorporated recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of KALYDECO in people with cystic fibrosis (CF) ages 18 and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
- CHMP Recommends EU Approval Of VIZAMYL (Flutemetamol F18 Injection) For PET Imaging Of Beta Amyloid Plaque
- Agenus Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation
- Leading Foundations Publish Recommendations To Accelerate Drug Repurposing For Neurodegenerative Diseases
- Cook Pharmica, LLC And Selexis SA Establish Customized Biologic Drug Development And Manufacturing Services Platform
FEATURED PRODUCTS AND SERVICES
High Porous Sintered Materials
International Stability Programs
Liquid-Filled Capsules
Patheon is one of the few companies capable and approved to develop and manufacture pharmaceuticals in both hard shell capsules and softgels; and no other company has deeper experience and resources.
Hydrogen Generator
PREMIER SERVICE PROVIDER
ARCHIVED NEWSLETTER
- 07.07.14 -- Innovative Multimode Plate Reader Launched
- 06.06.14 -- Positive Data On Humanized Antibody In Two Models Of Osteoarthritis Announced
- 05.02.14 -- Integrated Phenotypic Screening And Target Deconvolution For Drug Discovery
- 04.04.14 -- Disposable Purification Solution To Lower Cost And Accelerate Drug Development
- 03.07.14 -- Investment In FISH Technologies For Leukemia And Lymphoma Testing
